Evaluating urine tests for detecting bladder cancer
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney
Lahey Clinic · NCT00872495
This study is testing if urine tests that look for DNA and proteins can help detect bladder and kidney cancers in patients undergoing treatment or with a history of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Lahey Clinic (other) |
| Locations | 1 site (Burlington, Massachusetts) |
| Trial ID | NCT00872495 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of analyzing DNA and protein material found in urine for the detection of urothelial cancer, specifically bladder and kidney cancers. By examining these non-invasive assays, the study seeks to understand how they can aid in predicting cancer behavior, including remission and recurrence rates. The research focuses on patients undergoing procedures related to bladder cancer, including nephroureterectomy and cystectomy, as well as those with recurrent disease. A control group will also be included to compare results with individuals who have no known bladder cancer.
Who should consider this trial
Good fit: Ideal candidates include patients over 18 years old who are scheduled for procedures related to bladder cancer or have recurrent disease.
Not a fit: Patients under 18 years of age or those without any evidence of bladder cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and non-invasive methods for early detection and monitoring of bladder cancer.
How similar studies have performed: Previous studies have explored non-invasive assays for bladder cancer detection, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled to have a nephroureterectomy, cystectomy, cytoscopy (newly diagnosed bladder cancer and those with recurrent disease in follow up) * Control Group: No known evidence of bladder cancer-one urine sample * \> than 18 years of age Exclusion Criteria: * \< than 18 years of age
Where this trial is running
Burlington, Massachusetts
- Lahey Clinic, Inc. — Burlington, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Kimberly Rieger-Christ, PhD — Lahey Clinic, Inc.
- Study coordinator: Kimberly Rieger-Christ, PhD
- Email: Kimberly.R.Christ@lahey.org
- Phone: 781-744-2969
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Urothelial Cancer, Cancer, Bladder Neoplasms, Urinary Bladder Cancer